- Home
- XAIR vs PHIO Comparison
XAIR vs PHIO Comparison
Compare XAIR & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | PHIO |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 12.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XAIR | PHIO |
|---|---|---|
| Price | $0.88 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $11.00 | $10.67 |
| AVG Volume (30 Days) | 144.0K | ★ 374.9K |
| Earning Date | 02-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,802,000.00 | N/A |
| Revenue This Year | $128.45 | N/A |
| Revenue Next Year | $153.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $0.67 | $0.97 |
| 52 Week High | $10.40 | $9.79 |
Technical Indicators
Market Signals| Indicator | XAIR | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 47.48 |
| Support Level | $0.78 | $1.00 |
| Resistance Level | $0.98 | $1.22 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 69.06 | 68.23 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.